BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 20043814)

  • 1. Up-regulation of hypoxia-inducible factor (HIF)-1α and HIF-target genes in cortical neurons by the novel multifunctional iron chelator anti-Alzheimer drug, M30.
    Avramovich-Tirosh Y; Bar-Am O; Amit T; Youdim MB; Weinreb O
    Curr Alzheimer Res; 2010 Jun; 7(4):300-6. PubMed ID: 20043814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The novel multi-target iron chelator, M30 modulates HIF-1α-related glycolytic genes and insulin signaling pathway in the frontal cortex of APP/PS1 Alzheimer's disease mice.
    Mechlovich D; Amit T; Bar-Am O; Mandel S; Youdim MB; Weinreb O
    Curr Alzheimer Res; 2014 Feb; 11(2):119-27. PubMed ID: 24359498
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel molecular targets of the neuroprotective/neurorescue multimodal iron chelating drug M30 in the mouse brain.
    Kupershmidt L; Weinreb O; Amit T; Mandel S; Bar-Am O; Youdim MB
    Neuroscience; 2011 Aug; 189():345-58. PubMed ID: 21570450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuroprotective and neuritogenic activities of novel multimodal iron-chelating drugs in motor-neuron-like NSC-34 cells and transgenic mouse model of amyotrophic lateral sclerosis.
    Kupershmidt L; Weinreb O; Amit T; Mandel S; Carri MT; Youdim MB
    FASEB J; 2009 Nov; 23(11):3766-79. PubMed ID: 19638399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multi-target, neuroprotective and neurorestorative M30 improves cognitive impairment and reduces Alzheimer's-like neuropathology and age-related alterations in mice.
    Kupershmidt L; Amit T; Bar-Am O; Weinreb O; Youdim MB
    Mol Neurobiol; 2012 Aug; 46(1):217-20. PubMed ID: 22847630
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The novel multi-target iron chelating-radical scavenging compound M30 possesses beneficial effects on major hallmarks of Alzheimer's disease.
    Kupershmidt L; Amit T; Bar-Am O; Youdim MB; Weinreb O
    Antioxid Redox Signal; 2012 Sep; 17(6):860-77. PubMed ID: 22360429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular targets of the multifunctional iron-chelating drug, M30, in the brains of mouse models of type 2 diabetes mellitus.
    Mechlovich D; Amit T; Bar-Am O; Weinreb O; Youdim MB
    Br J Pharmacol; 2014 Dec; 171(24):5636-49. PubMed ID: 25073425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuroprotection by the multitarget iron chelator M30 on age-related alterations in mice.
    Kupershmidt L; Amit T; Bar-Am O; Youdim MB; Weinreb O
    Mech Ageing Dev; 2012 May; 133(5):267-74. PubMed ID: 22426424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel antioxidant multitarget iron chelator M30 protects hepatocytes against ethanol-induced injury.
    Xiao J; Lv Y; Lin B; Tipoe GL; Youdim MB; Xing F; Liu Y
    Oxid Med Cell Longev; 2015; 2015():607271. PubMed ID: 25722794
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multi target neuroprotective and neurorestorative anti-Parkinson and anti-Alzheimer drugs ladostigil and m30 derived from rasagiline.
    Youdim MB
    Exp Neurobiol; 2013 Mar; 22(1):1-10. PubMed ID: 23585716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protection from oxidative stress-induced apoptosis in cortical neuronal cultures by iron chelators is associated with enhanced DNA binding of hypoxia-inducible factor-1 and ATF-1/CREB and increased expression of glycolytic enzymes, p21(waf1/cip1), and erythropoietin.
    Zaman K; Ryu H; Hall D; O'Donovan K; Lin KI; Miller MP; Marquis JC; Baraban JM; Semenza GL; Ratan RR
    J Neurosci; 1999 Nov; 19(22):9821-30. PubMed ID: 10559391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The path from anti Parkinson drug selegiline and rasagiline to multifunctional neuroprotective anti Alzheimer drugs ladostigil and m30.
    Youdim MB
    Curr Alzheimer Res; 2006 Dec; 3(5):541-50. PubMed ID: 17168653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypoxia-inducible factors as neuroprotective agent in Alzheimer's disease.
    Ashok BS; Ajith TA; Sivanesan S
    Clin Exp Pharmacol Physiol; 2017 Mar; 44(3):327-334. PubMed ID: 28004401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. From anti-Parkinson's drug rasagiline to novel multitarget iron chelators with acetylcholinesterase and monoamine oxidase inhibitory and neuroprotective properties for Alzheimer's disease.
    Zheng H; Amit T; Bar-Am O; Fridkin M; Youdim MB; Mandel SA
    J Alzheimers Dis; 2012; 30(1):1-16. PubMed ID: 22387411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases.
    Youdim MB; Fridkin M; Zheng H
    Mech Ageing Dev; 2005 Feb; 126(2):317-26. PubMed ID: 15621213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The novel multitarget iron chelating and propargylamine drug M30 affects APP regulation and processing activities in Alzheimer's disease models.
    Amit T; Bar-Am O; Mechlovich D; Kupershmidt L; Youdim MBH; Weinreb O
    Neuropharmacology; 2017 Sep; 123():359-367. PubMed ID: 28571715
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multifunctional neuroprotective derivatives of rasagiline as anti-Alzheimer's disease drugs.
    Weinreb O; Mandel S; Bar-Am O; Yogev-Falach M; Avramovich-Tirosh Y; Amit T; Youdim MB
    Neurotherapeutics; 2009 Jan; 6(1):163-74. PubMed ID: 19110207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases: in vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition.
    Zheng H; Gal S; Weiner LM; Bar-Am O; Warshawsky A; Fridkin M; Youdim MB
    J Neurochem; 2005 Oct; 95(1):68-78. PubMed ID: 16181413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Propargylamine containing compounds as modulators of proteolytic cleavage of amyloid-beta protein precursor: involvement of MAPK and PKC activation.
    Bar-Am O; Amit T; Weinreb O; Youdim MB; Mandel S
    J Alzheimers Dis; 2010; 21(2):361-71. PubMed ID: 20555137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Promises of novel multi-target neuroprotective and neurorestorative drugs for Parkinson's disease.
    Youdim MB; Kupershmidt L; Amit T; Weinreb O
    Parkinsonism Relat Disord; 2014 Jan; 20 Suppl 1():S132-6. PubMed ID: 24262165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.